The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye

References

• No authors listedThe definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007)Ocul Surf200752759217508116
   PubMed Web of Science ®Google Scholar
• No authors listedThe epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007)Ocul Surf2007529310717508117
   PubMed Web of Science ®Google Scholar
• PflugfelderSCCorralesRMde PaivaCST helper cytokines in dry eye diseaseExp Eye Res201311711812524012834
   PubMed Web of Science ®Google Scholar
• StevensonWChauhanSKDanaRDry eye disease: an immune-mediated ocular surface disorderArch Ophthalmol201213019010022232476
   PubMedGoogle Scholar
• UchinoMSchaumbergDADry eye disease: impact on quality of life and visionCurr Ophthalmol Rep201312515723710423
   PubMedGoogle Scholar
• DogruMTsubotaKPharmacotherapy of dry eyeExpert Opin Pharmacother201112332533421214414
   PubMed Web of Science ®Google Scholar
• RidderWH3rdTomlinsonAHuangJFLiJImpaired visual performance in patients with dry eyeOcul Surf201191425521338568
   PubMed Web of Science ®Google Scholar
• SullivanBDCrewsLAMessmerEMCorrelations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: clinical implicationsActa Ophthalmol201492216116623279964
   PubMed Web of Science ®Google Scholar
• SchmidlDWitkowskaKJKayaSThe association between subjective and objective parameters for the assessment of dry-eye syndromeInvest Ophthalmol Vis Sci20155631467147225650419
   PubMed Web of Science ®Google Scholar
• MiljanovićBDanaRSullivanDASchaumbergDAImpact of dry eye syndrome on vision-related quality of lifeAm J Ophthalmol2007143340941517317388
   PubMed Web of Science ®Google Scholar
• LiMGongLChapinWJZhuMAssessment of vision-related quality of life in dry eye patientsInvest Ophthalmol Vis Sci20125395722572722836767
   PubMed Web of Science ®Google Scholar
• LeQZhouXGeLWuLHongJXuJImpact of dry eye syndrome on vision-related quality of life in a non-clinic-based general populationBMC Ophthalmol2012122222799274
   PubMed Web of Science ®Google Scholar
• PaulsenAJCruickshanksKJFischerMEDry eye in the Beaver Dam offspring study: prevalence, risk factors, and health-related quality of lifeAm J Ophthalmol2014157479980624388838
   PubMed Web of Science ®Google Scholar
• KaidoMMatsumotoYShigenoYIshidaRDogruMTsubotaKCorneal fluorescein staining correlates with visual function in dry eye patientsInvest Ophthalmol Vis Sci201152139516952222110071
   PubMed Web of Science ®Google Scholar
• RidderWH3rdZhangYHuangJFEvaluation of reading speed and contrast sensitivity in dry eye diseaseOptom Vis Sci2013901374423222922
   PubMed Web of Science ®Google Scholar
• DeschampsNRicaudXRabutGLabbeABaudouinCDenoyerAThe impact of dry eye disease on visual performance while drivingAm J Ophthalmol20131561e3.184e3.18923706501
   PubMed Web of Science ®Google Scholar
• SallKStevensonODMundorfTKReisBLCsA Phase III Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye diseaseOphthalmology2000107463163910768324
   PubMed Web of Science ®Google Scholar
• RaoSNTopical cyclosporine 0.05% for the prevention of dry eye disease progressionJ Ocul Pharmacol Ther201026215716420415623
   PubMed Web of Science ®Google Scholar
• StevensonDTauberJReisBLEfficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. Cyclosporin A Phase II Study GroupOphthalmology2000107596797410811092
   PubMed Web of Science ®Google Scholar
• OuslerG3rdDevriesDKKarpeckiPMCiolinoJBAn evaluation of Retaine™ ophthalmic emulsion in the management of tear film stability and ocular surface staining in patients diagnosed with dry eyeClin Ophthalmol2015923524325709384
   PubMed Web of Science ®Google Scholar
• AbelsonRLaneKJRodriguezJValidation and verification of the OPI 2.0 SystemClin Ophthalmol2012661362222570541
   PubMedGoogle Scholar
• McDonnellPJDry eye: an underrecognized and undertreated diseaseJohns Hopkins Adv Stud Ophthalmol20129114
   Google Scholar
• TrattlerWBwebpage on the InternetPrevalence of dry eye in surgical populationsASCRS EyeWorld CME Supplement32013 Available from: http://www.eyeworld.org/supplements/oct-2013/Allergan_supplement_October2013.pdfAccessed September 5, 2015
   Google Scholar
• McDonnellPJPflugfelderSSchiffmanRMProgression of Ocular Findings (PROOF) study of the natural history of dry eye: study design and baseline patient characteristicsInvest Ophthalmol Vis Sci201354154338 ARVO E-Abstract 4338.
   Web of Science ®Google Scholar
• Restasis^® (cyclosporine ophthalmic emulsion) [prescribing information]Irvine, CAAllergan, Inc2014
   Google Scholar
• KimECChoiJSJooCKA comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndromeAm J Ophthalmol20091472e3.206e3.21318848318
   PubMed Web of Science ®Google Scholar
• DemiryayEYaylaliVCetinENYildirimCEffects of topical cyclosporine A plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndromeEye Contact Lens201137531231521792057
   PubMed Web of Science ®Google Scholar
• WanKHChenLJYoungALEfficacy and safety of topical 0.05% cyclosporine eye drops in the treatment of dry eye syndrome: a systematic review and meta-analysisOcul Surf201513321322526045239
   PubMed Web of Science ®Google Scholar
• UtineCASternMAkpekEKClinical review: topical ophthalmic use of cyclosporin AOcul Immunol Inflamm201018535236120735287
   PubMed Web of Science ®Google Scholar
• PrabhasawatPTesavibulNMahawongWA randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunctionCornea201231121386139323135530
   PubMed Web of Science ®Google Scholar
• QiaoJYanXEmerging treatment options for meibomian gland dysfunctionClin Ophthalmol201371797180324043929
   PubMedGoogle Scholar
• WanKHChenLJRongSSPangCPYoungALTopical cyclosporine in the treatment of allergic conjunctivitis: a meta-analysisOphthalmology2013120112197220323743438
   PubMed Web of Science ®Google Scholar
• ZicariAMZicariANebbiosoMHigh-mobility group box-1 (HMGB-1) and serum soluble receptor for advanced glycation end products (sRAGE) in children affected by vernal keratoconjunctivitisPediatr Allergy Immunol2014251576324236762
   PubMed Web of Science ®Google Scholar
• HomMMUse of cyclosporine 0.05% ophthalmic emulsion for contact lens-intolerant patientsEye Contact Lens200632210911116538135
   PubMedGoogle Scholar
• SchechterBAKatzRSFriedmanLSEfficacy of topical cyclosporine for the treatment of ocular rosaceaAdv Ther200926665165919551353
   PubMed Web of Science ®Google Scholar
• SahinABozkurtBIrkecMTopical cyclosporine A in the treatment of superior limbic keratoconjunctivitis: a long-term follow-upCornea200827219319518216575
   PubMed Web of Science ®Google Scholar